Nom du produit:4-Chloro-6,7-dimethoxyquinazoline
IUPAC Name:4-chloro-6,7-dimethoxyquinazoline
- CAS：13790-39-1
- Formule moléculaire：C10H9ClN2O2
- Pureté：98%
- Numéro de catalogue：CM121387
- Poids moléculaire：224.64
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:13790-39-1
- Formule moléculaire:C10H9ClN2O2
- Point de fusion:-
- Code SMILES:COC1=CC2=NC=NC(Cl)=C2C=C1OC
- Densité:
- Numéro de catalogue:CM121387
- Poids moléculaire:224.64
- Point d'ébullition:345.5°C at 760 mmHg
- N° Mdl:MFCD01570172
- Stockage:Keep in inert atmosphere, store at 2-8°C.
Category Infos
- Quinazolines
- Quinazolines belong to heterocyclic chemistry, also known as 1,3-naphthalenes. The backbone consists of two six-membered aromatic rings fused to each other, with two nitrogen atoms at positions 1 and 3 on the backbone. The presence of these two nitrogen atoms in quinazoline increases its importance in pharmaceutical and biological reactions. Quinazolines and their derivatives are among the most important heterocyclic compounds due to their diverse chemical reactivity and important range of biological activities.
Column Infos
- Fruquintinib
- November 08, 2023, FDA has approved FRUZAQLA(fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
FRUZAQLA is the first and only selective inhibitor of all three VEGF receptor kinases approved in the U.S. for previously treated mCRC regardless of biomarker status.
Recherche 
+86 21 5895 0110 
